Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
6 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
3 Apr 24
8-K
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 Jan 24
8-K
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 Dec 23
8-K
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 Dec 23
424B5
Prospectus supplement for primary offering
11 Dec 23
8-K
Entry into a Material Definitive Agreement
11 Dec 23
8-K
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Other Events
27 Sep 23
8-K
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
19 Sep 23
8-K
Other Events
12 Sep 23
8-K
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
1 Sep 23
8-K
Regulation FD Disclosure
11 Aug 23
8-K
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
2 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
19 Jul 23
8-K
Departure of Directors or Certain Officers
11 Jul 23
8-K
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
7 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
8-K
CytoSorbents Reports First Quarter 2023 Results
2 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Other Events
26 Apr 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
20 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
8-K
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
CytoSorbents Issues Stockholder Letter and Reports Preliminary
31 Jan 23
8-K
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement
29 Dec 22
8-K
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
16 Nov 22
8-K
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results
3 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
Latest ownership filings
4
Edward Raymond Jones
4 Apr 24
4
Efthymios Deliargyris
4 Apr 24
4
Alan D. Sobel
4 Apr 24
4
KATHLEEN P. BLOCH
4 Apr 24
4
MICHAEL G. BATOR
4 Apr 24
4
Vincent Capponi
4 Apr 24
4
Jiny Kim
4 Apr 24
4
Phillip P. Chan
4 Apr 24
4
Efthymios Deliargyris
2 Apr 24
4
Vincent Capponi
2 Apr 24
4
KATHLEEN P. BLOCH
2 Apr 24
4
Phillip P. Chan
2 Apr 24
SC 13G
AVENIR CORP
14 Feb 24
SC 13G
Granahan Investment Management, LLC
14 Feb 24
SC 13G
Skylands Capital, LLC
8 Jan 24
4
Alan D. Sobel
15 Dec 23
4
Efthymios Deliargyris
15 Dec 23
4
Vincent Capponi
15 Dec 23
4
MICHAEL G. BATOR
15 Dec 23
4
Edward Raymond Jones
15 Dec 23
4
KATHLEEN P. BLOCH
15 Dec 23
4
Jiny Kim
15 Dec 23
4
Phillip P. Chan
15 Dec 23
4
KATHLEEN P. BLOCH
20 Sep 23
3
Alex D'Amico
15 Aug 23
4
MICHAEL G. BATOR
8 Aug 23
4
KATHLEEN P. BLOCH
11 Jul 23
4
Phillip P. Chan
11 Jul 23
4
MICHAEL G. BATOR
11 Jul 23
4
Alan D. Sobel
11 Jul 23
4
Edward Raymond Jones
11 Jul 23
4
Jiny Kim
11 Jul 23
4
Vincent Capponi
11 Jul 23
4
Efthymios Deliargyris
11 Jul 23
4
KATHLEEN P. BLOCH
30 May 23
4
KATHLEEN P. BLOCH
12 May 23
4
Vincent Capponi
5 Apr 23
4
Phillip P. Chan
5 Apr 23
4
Alan D. Sobel
1 Mar 23
SC 13G/A
AVENIR CORP
14 Feb 23